[{"orgOrder":0,"company":"Debiopharm","sponsor":"3B Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Debio 0228","moa":"CA IX","graph1":"Oncology","graph2":"Discovery","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"2","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"68-Ga DPI-4452","moa":"CAIX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DPI-4452","moa":"||CAIX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Debio 1562","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Nephrology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Undisclosed","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":1.0700000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.0700000000000001,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Merck & Co"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afabicin","moa":"Bacterial DNA gyrase||Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afabicin","moa":"Bacterial DNA gyrase||Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Afabicin","moa":"Bacterial DNA gyrase||Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Afabicin","moa":"Bacterial DNA gyrase||Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Afabicin","moa":"Bacterial DNA gyrase||Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Afabicin","moa":"Bacterial DNA gyrase||Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Afabicin","moa":"Enoyl-[acyl-carrier-protein] reductase (FabI)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Gardp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Debio 1453","moa":"FabI","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Gardp","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Gardp"},{"orgOrder":0,"company":"Debiopharm","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Debio 1453","moa":"FabI","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ CARB-X"},{"orgOrder":0,"company":"Debiopharm","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Debio 1453","moa":"FabI","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ CARB-X"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Biomedical Advanced Research and Development Authority | Wellcome Trust | Germany's Federal Ministry of Research, Technology and Space (BMFTR) | Global Antimicrobial Resistance Innovation Fund | Novo Nordisk Foundation (NNF)","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Debio 1453P","moa":"FabI","graph1":"Undisclosed","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Debiopharm \/ Biomedical Advanced Research and Development Authority | Wellcome Trust | Germany's Federal Ministry of Research, Technology and Space (BMFTR) | Global Antimicrobial Resistance Innovation Fund | Novo Nordisk Foundation (NNF)","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Biomedical Advanced Research and Development Authority | Wellcome Trust | Germany's Federal Ministry of Research, Technology and Space (BMFTR) | Global Antimicrobial Resistance Innovation Fund | Novo Nordisk Foundation (NNF)"},{"orgOrder":0,"company":"Debiopharm","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Debio-1453","moa":"FabI","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ CARB-X"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Caris Life Sciences | Optimal Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Debio 1347","moa":"FGFR1\/FGFR2\/FGFR3","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Debiopharm \/ Caris Life Sciences | Optimal Research","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Caris Life Sciences | Optimal Research"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Debio 1347","moa":"FGFR1\/FGFR2\/FGFR3","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Quintiles Inc"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH AFRICA","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Dexa Medica","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDONESIA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Knight Therapeutics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Debio 0932","moa":"HSP90","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Debio 0932","moa":"HSP90","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Debiopharm \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Syneos Health"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Naratuximab Emtansine","moa":"||Leukocyte antigen CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Repare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Repare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RP-6306","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"||Somatostatin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Debio 4126","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Debio 4126","moa":"SST receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"177-Lu DPI-4452","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Minigastrin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Debio 0432","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Debio 1562M","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Debio 4228","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Debio 4326","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"SunRock Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"SRB19","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ SunRock Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ SunRock Biopharma"},{"orgOrder":0,"company":"Debiopharm","sponsor":"SunRock Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"SRB21","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"FT-3171","moa":"USP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ MEDSIR","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ MEDSIR"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"MEDSIR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"3","companyTruncated":"Debiopharm \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Oncodesign Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Oncodesign"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Alkyon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Alkyon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Alkyon Therapeutics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Whitelab Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Whitelab Genomics","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Whitelab Genomics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Whitelab Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Whitelab Genomics","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Whitelab Genomics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"SunRock Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"SRB21","moa":"HER2\/HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ Debiopharm"}]
Find Clinical Drug Pipeline Developments & Deals by Debiopharm
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
